Aldeyra Therapeutics (ALDX) Long-Term Deferred Tax (2024)
Aldeyra Therapeutics (ALDX) posted Long-Term Deferred Tax of $267261.0 for Q4 2024, little changed on a QoQ basis from $267261.0 in Q3 2024.
Aldeyra Therapeutics (ALDX) Long-Term Deferred Tax (2024) Analysis & Trends
Aldeyra Therapeutics' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $267261.0 for Q4 2024.
- Quarterly Long-Term Deferred Tax changed N/A year-over-year to $267261.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $267261.0 (changed N/A YoY) and the FY2024 annual result came in at $267261.0, changed N/A from the prior year.
- Long-Term Deferred Tax was $267261.0 for Q4 2024 at Aldeyra Therapeutics, roughly flat from $267261.0 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $267261.0 in Q3 2024 and bottomed at $267261.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn |
| 10 | Aldeyra Therapeutics | 93.19 Mn | 93.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 267,261.00 |
| Sep 30, 2024 | 267,261.00 |